NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

PMV Pharmaceuticals, Inc. (PMVP) Stock Analysis

PMV Pharmaceuticals, Inc. (PMVP) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

PMVP

$1.29

+$0.05 (+4.03%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PMVP with… →

PMVP Key Statistics

As of Sep 4, 2026
Trading
Open
$1.24
Previous Close
$1.24
Day's Range
1.24–1.35
52-Week Range
1.02–1.88
Volume
530.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.37
Valuation
Market Cap
$68.96M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.42
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$77.74M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
53.46M
1-Year Return
−10.42%
Dividend and dates
Earnings Date
November 16, 2026estimated
Avg Volume
424.33K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PMVP Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+3.20%
2025−17.22%
2024−51.29%
2023−64.37%
2022−62.34%
2021−62.45%
2020 (partial year)+63.98%

As of September 4, 2026.

PMVP Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$77.74M—
2024$0.00−$58.71M—
2023$0.00−$68.96M—
2022$0.00−$73.32M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$86.21M−$77.74M—
2024$0.00—−$85.45M−$58.71M—
2023$0.00—−$80.13M−$68.96M—
2022$0.00—−$77.04M−$73.32M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PMVP Valuation vs Biotechnology Median

Median of 656 stocks
MetricPMVPBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values PMV Pharmaceuticals, Inc. (PMVP) at $68.96M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 54 employees.

The 52-week range on file runs from $1.02 to $1.88. PMVP last closed at $1.29 on September 4, 2026. That is +$0.05 (+4.03%) against the previous close. The latest close sits 26.47% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $77.74M. Profit margin runs at 0%. Trailing earnings per share are −1.42.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Over the trailing twelve months the price has returned −10.42%. Measured over 5 years, that is −45.96% a year compounded. Beta against the wider market is reported at 1.37. Annualized volatility over the trailing 5 years is 76.76%.

Growth & Income

No dividend is on file for PMVP.

So far in 2026 the price is +3.20%. The strongest complete calendar year on file is 2025 at −17.22%; the weakest is 2023 at −64.37%. Of the 5 complete calendar years on file, 0 finished higher.

Peer Comparison

PMV Pharmaceuticals, Inc. (PMVP) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
PMV Pharmaceuticals, Inc. PMVP $68.96M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. PMV Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New Jersey.

Visit website →